Phase 2 Prostate Cancer Trial, Recruiting NCT06237179 Sponsor: Virginia Commonwealth University Condition: Prostate Cancer
Back to Prostate Cancer

Phase 2 Prostate Cancer Trial, Recruiting

NCT06237179
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with stage II, III, or IV prostate cancer
  • People who are currently receiving androgen deprivation therapy (ADT), whether taken on and off or continuously
  • People who have already completed a primary treatment aimed at curing the cancer, such as surgery to remove the prostate or radiation therapy
  • People who are between 41 and 85 years of age
  • People who are willing to sign a consent form that includes a privacy authorization
  • People who do not have hearing or vision problems that would prevent them from using a phone or following a normal conversation
  • People who are able to participate in group sessions by computer, smartphone, or phone call, and who agree to having an interview recorded
  • People who do not have a serious medical condition that would make it unsafe to take part in an exercise program
  • People who speak English

Who may not be able to join:

  • People who are unable to have an MRI scan, for example due to metal implants in the body, being unable to lie flat, or having claustrophobia
  • People who have medical reasons why exercise testing would not be safe for them (confirm with trial site)
  • People who have a pre-existing serious heart condition or heart failure
  • People who have an active illness or infection at the time of the trial
  • People whose hemoglobin (a measure of red blood cells) is below 7.0 grams per decilitre
  • People whose platelet count (cells that help blood clot) is below a certain low level

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Alexander R Lucas, PhD, Virginia Commonwealth University

Phone: 804 628-6610

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Registry
ClinicalTrials.gov
Start date
21 February 2024
Est. completion
31 January 2028

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Change from baseline in maximal exercise capacity (VO2 peak) at 12 weeks; Change from baseline in sub-maximal exercise capacity (6MWD) at 12 weeks

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov